PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsCarvedilol
Carvedilol
Carvedilol, Coreg (carvedilol) is a small molecule pharmaceutical. Carvedilol was first approved as Coreg on 1995-09-14. It is used to treat angina pectoris, heart failure, hypertension, and myocardial infarction in the USA. The pharmaceutical is active against beta-1 adrenergic receptor and beta-2 adrenergic receptor. In addition, it is known to target ryanodine receptor 2.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Carvedilol, Coreg (discontinued: Carvedilol, Coreg)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Carvedilol
Tradename
Company
Number
Date
Products
COREGWaylis TherapeuticsN-020297 RX1995-09-14
4 products, RLD
Carvedilol phosphate
Tradename
Company
Number
Date
Products
COREG CRWaylis TherapeuticsN-022012 DISCN2006-10-20
4 products, RLD
Hide discontinued
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Carvedilol Phosphate, Coreg Cr, Woodward
81012092025-09-11DP
ATC Codes
C: Cardiovascular system drugs
— C07: Beta-adrenergic blocking agents
— C07A: Beta blocking agents
— C07AG: Alpha and beta blocking agents
— C07AG02: Carvedilol
— C07F: Beta blocking agents, other combinations
— C07FX: Beta blocking agents, other combinations
— C07FX06: Carvedilol and ivabradine
HCPCS
No data
Clinical
Clinical Trials
316 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———2————2
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCarvedilol
INNcarvedilol
Description
Carvedilol is a member of the class of carbazoles that is an adrenergic antagonist with non-selective beta- and alpha-1 receptor blocking properties which helps in the management of congestive heart failure. It has a role as a beta-adrenergic antagonist, an antihypertensive agent, an alpha-adrenergic antagonist, a vasodilator agent and a cardiovascular drug. It is a member of carbazoles, a secondary alcohol and a secondary amino compound.
Classification
Small molecule
Drug classvasodilators (undefined group)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
COc1ccccc1OCCNCC(O)COc1cccc2[nH]c3ccccc3c12
Identifiers
PDB—
CAS-ID72956-09-3
RxCUI—
ChEMBL IDCHEMBL723
ChEBI ID3441
PubChem CID2585
DrugBankDB01136
UNII ID0K47UL67F2 (ChemIDplus, GSRS)
Target
Agency Approved
ADRB1
ADRB1
ADRB2
ADRB2
Organism
Homo sapiens
Gene name
ADRB1
Gene synonyms
ADRB1R, B1AR
NCBI Gene ID
Protein name
beta-1 adrenergic receptor
Protein synonyms
adrenergic, beta-1-, receptor, Beta-1 adrenoceptor, Beta-1 adrenoreceptor
Uniprot ID
Mouse ortholog
Adrb1 (11554)
beta-1 adrenergic receptor (P34971)
Alternate
RYR2
RYR2
Organism
Homo sapiens
Gene name
RYR2
Gene synonyms
NCBI Gene ID
Protein name
ryanodine receptor 2
Protein synonyms
Cardiac muscle ryanodine receptor, Cardiac muscle ryanodine receptor-calcium release channel, cardiac-type ryanodine receptor, islet-type ryanodine receptor, kidney-type ryanodine receptor, ryanodine receptor 2 (cardiac), Type 2 ryanodine receptor
Uniprot ID
Mouse ortholog
Ryr2 (20191)
ryanodine receptor 2 (Q9ERN6)
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Carvedilol
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 36,810 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
23,369 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use